Etcembly Ltd
Drug Discovery
- Website
- https://www.etcembly.com/
- Membership category
- Corporate
Atlas Building, Harwell Campus, Didcot, Oxfordshire, OX11 0QX, United Kingdom
Etcembly Ltd at a glance
Etcembly utilises the power of machine learning to discover and engineer T Cell Receptors (TCRs) to develop cancer immunotherapies.
About Etcembly Ltd
Etcembly, based in Harwell in Oxfordshire, was launched in 2020 has 25 employees. It is supported by funding from a group of private investors. It is the world’s first company to leverage machine learning/artificial intelligence to discover safe, and potent T cell receptors (TCRs) for immunotherapy. Etcembly has developed a sophisticated search engine, EMLy™ to discover and engineer the next generation of TCR therapeutics.
With the recent approval of KIMMTRAK for uveal melanoma, TCRs are gaining considerable interest for treating a wide range of diseases including cancer and auto-immune conditions, either in engineered T cell therapies or as standalone bi-specific immune engagers that bring immune cells directly in contact with tumours. However, the field has been held back by the slow pace of TCR discovery and engineering. TCRs bind to their targets with low affinity and are inherently cross-reactive, limiting their potency and risking side effects.
Etcembly’s rapid prediction/validation cycles accelerate the development of high quality and efficacious candidates. The company has also developed its own novel lab on a chip technology to interrogate TCR repertoires at scale, serving the foundation of solid datasets for EMLy to learn from.
